Which of the following should not be discussed with the patient regarding calcium channel blocker therapy?
A. This medication may cause you to get some swelling in your ankles. B. Damage to your liver is possible and should be carefully watched for. C. The medication you are given is used to reduce your BP. D. a and c • The withdrawal syndrome following the abrupt cessation of a beta-antagonist is characterized by: A. Tachycardia. B. Elevation of BP. C. An upregulation of cardiac betareceptors. D. All of the above. • The ultimate concern with a patient stopping beta-blockers abruptly is: A. Rebound hypertension. B. Arrhythmia. C. Serotonin syndrome. D. Complications of hypertension. • Which of the following is the most likely pharmacologic rationale for slowly tapering a patient off of a beta-antagonist in order to avoid the withdrawal syndrome? A. A slow tapering of beta-antagonist therapy will allow sympathetic nerves to readjust their norepinephrine release. B. A slow tapering of beta-antagonist therapy will allow for cardiac tissue to readjust its betareceptor population. C. A slow tape
